Neuren Pharmaceuticals Ltd. (NURPF)
14.28
+0.34
(+2.42%)
USD |
OTCM |
Oct 02, 16:00
Neuren Pharmaceuticals Max Drawdown (5Y) : 61.55% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 61.55% |
| August 31, 2026 | 61.55% |
| July 31, 2026 | 61.55% |
| June 30, 2026 | 61.55% |
| May 31, 2026 | 65.56% |
| April 30, 2026 | 66.09% |
| March 31, 2026 | 66.09% |
| February 28, 2026 | 66.09% |
| January 31, 2026 | 66.09% |
| December 31, 2025 | 66.09% |
| November 30, 2025 | 67.76% |
| October 31, 2025 | 74.35% |
| September 30, 2025 | 74.35% |
| August 31, 2025 | 74.35% |
| July 31, 2025 | 74.35% |
| June 30, 2025 | 74.35% |
| May 31, 2025 | 74.35% |
| April 30, 2025 | 74.35% |
| March 31, 2025 | 76.92% |
| February 28, 2025 | 79.85% |
| January 31, 2025 | 79.85% |
| December 31, 2024 | 79.85% |
| November 30, 2024 | 79.85% |
| October 31, 2024 | 79.85% |
| September 30, 2024 | 79.85% |
| Date | Value |
|---|---|
| August 31, 2024 | 79.85% |
| July 31, 2024 | 79.85% |
| June 30, 2024 | 79.85% |
| May 31, 2024 | 79.85% |
| April 30, 2024 | 79.85% |
| March 31, 2024 | 79.85% |
| February 29, 2024 | 79.85% |
| January 31, 2024 | 79.85% |
| December 31, 2023 | 79.85% |
| November 30, 2023 | 79.85% |
| October 31, 2023 | 79.85% |
| September 30, 2023 | 79.85% |
| August 31, 2023 | 79.85% |
| July 31, 2023 | 79.85% |
| June 30, 2023 | 79.85% |
| May 31, 2023 | 79.85% |
| April 30, 2023 | 79.85% |
| March 31, 2023 | 79.85% |
| February 28, 2023 | 79.85% |
| January 31, 2023 | 79.85% |
| December 31, 2022 | 79.85% |
| November 30, 2022 | 79.85% |
| October 31, 2022 | 95.83% |
| September 30, 2022 | 95.83% |
| August 31, 2022 | 95.83% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Percheron Therapeutics Ltd. | 99.63% |
| Starpharma Holdings Ltd. | 97.54% |
| Mayne Pharma Group Ltd. | 89.56% |
| Acrux Ltd. | 99.51% |
| Zelira Therapeutics Ltd. | 99.60% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | 38.38 |
| Beta (5Y) | 1.249 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 84.61% |
| Historical Sharpe Ratio (5Y) | 0.6014 |
| Historical Sortino (5Y) | 1.902 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 20.94% |